Quick Answer
Janux Therapeutics, Inc. reported Total Assets of $1.00 billion for fiscal year 2025.
Janux Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $1.00B | -5.6% |
| 2024 | $1.06B | +179.0% |
| 2023 | $380.41M | +4.5% |
| 2022 | $364.01M | -4.2% |
| 2021 | $379.82M | +2242.1% |
| 2020 | $16.22M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.02B | +47.4% | -0.7% |
| June 30, 2025 | $1.03B | +49.3% | -1.8% |
| March 31, 2025 | $1.05B | +52.5% | -1.0% |
| December 31, 2024 | $1.06B | +179.0% | +52.7% |
| September 30, 2024 | $695.02M | +79.7% | +0.5% |
| June 30, 2024 | $691.41M | +102.5% | +0.4% |
| March 31, 2024 | $688.98M | +95.2% | +81.1% |
| December 31, 2023 | $380.41M | +4.5% | -1.7% |
- Janux Therapeutics, Inc. showed a decrease of -5.6% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Janux Therapeutics, Inc.’s total assets has grown by 6076.0% (from $16.22 million to $1.00 billion).
- The most recent figure is from Janux Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: